Evidence map›Paper›PMID 40186065›Full record

ArticleLeukemia2025

CLL cell-derived exosomes alter the immune and hematopoietic systems.

Ivo Veletic, David M Harris, Uri Rozovski, Maria Teresa S Bertilaccio, George A Calin, Koichi Takahashi, Ping Li, Zhiming Liu, Taghi Manshouri, Rares-Constantin Drula and 6 more

Abstract read
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Advancing Immunotherapy in Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ivo VeleticDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. iveletic@mdanderson.org.ORCID 0000-0001-5802-5313
David M HarrisDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Uri RozovskiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maria Teresa S BertilaccioDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2304-4618
George A CalinDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7427-0578
Koichi TakahashiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8027-9659
Ping LiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhiming LiuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Taghi ManshouriDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rares-Constantin DrulaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ken FurudateDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1272-5490
Muharrem MuftuogluDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8100-8554
Anwar HossainDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
William G WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7357-270X
Michael J KeatingDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zeev EstrovDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. zestrov@mdanderson.org.ORCID 0000-0002-1623-3613

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

The origins of immunosuppression, neutropenia, and anemia in patients with chronic lymphocytic leukemia (CLL) are not fully understood. Because in patients with CLL, circulating exosomes, which participate in cell-to-cell interactions, are CLL cell-derived, we examined whether those exosomes contribute to abnormal features of this disease. Our data revealed that CLL cell-derived exosomes engulfed by healthy donors' monocytes, fibrocytes, and lymphocytes altered target-cell gene and protein expression and suppressed normal hematopoiesis. CLL cell-derived exosomes increased normal monocytes' CD14 and CD16 expression such that it mimicked the accessory-cell profile and upregulated T cells' checkpoint PD-1 and CD160 protein levels, potentially reducing T-cell-mediated anti-CLL activity. In normal B cells, CLL cell-derived exosomes induced apoptosis and CD5 expression, suggesting that CLL cell-derived exosomes eliminate B cells and not all CD19

Indexed as

ExosomesHematopoiesisLeukemia, Lymphocytic, Chronic, B-CellApoptosisB-LymphocytesHumansMonocytes

Identifiers

PMID40186065
PMCPMC12133404

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.